Foster & Motley Inc. Sells 12,772 Shares of Bristol Myers Squibb Company $BMY

Foster & Motley Inc. cut its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 24.4% during the 4th quarter, Holdings Channel reports. The fund owned 39,643 shares of the biopharmaceutical company’s stock after selling 12,772 shares during the period. Foster & Motley Inc.’s holdings in Bristol Myers Squibb were worth $2,138,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the stock. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter valued at about $25,000. Harbor Capital Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the period. Beacon Financial Strategies CORP acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $38,000. KERR FINANCIAL PLANNING Corp bought a new stake in Bristol Myers Squibb in the 3rd quarter valued at about $35,000. Finally, JPL Wealth Management LLC acquired a new position in Bristol Myers Squibb during the 3rd quarter worth approximately $36,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Phase‑3 adolescent win for Camzyos strengthens BMY’s cardiovascular franchise — the SCOUT‑HCM trial met its primary endpoint with robust efficacy and no new safety signals, supporting label expansion into younger patients and longer commercial runway for the drug. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: FDA approval for a Hodgkin’s lymphoma combination therapy provides an immediate commercial lift and validates oncology execution — another approved product can help offset patent cliffs elsewhere. Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment
• Positive Sentiment: Value/income investor interest — Ariel Global Fund re‑added BMY citing pipeline strength and attractive valuation, which could signal renewed institutional demand. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Analyst/education pieces (Zacks, Yahoo) highlight potential upside from earnings surprises using Earnings ESP and note BMY’s recent outperformance relative to its history, but these are directional signals rather than new fundamentals. Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
• Neutral Sentiment: Market reports project growth in oncology and kidney cancer drug markets through 2030, underlining long‑term addressable market tailwinds for BMY but not immediate revenue changes. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Negative Sentiment: Some outlets note mixed analyst sentiment and questions around near‑term execution; investors should weigh recent approval and trial wins against prior earnings misses and heavy leverage on the balance sheet. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Barclays started coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Leerink Partners boosted their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Price Performance

BMY stock opened at $60.56 on Wednesday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The business has a 50-day simple moving average of $59.03 and a two-hundred day simple moving average of $52.45. The company has a market capitalization of $123.65 billion, a P/E ratio of 17.55, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the company earned $1.67 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.